lansoprazole has been researched along with Dyslipidemias in 2 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The prospective, open-label, randomized study aims to compare the efficacy of lansoprazole, a fast orally disintegrating proton pump inhibitor (PPI), and dexlansoprazole, a dual delayed release PPI, in patients with atypical symptoms of gastroesophageal reflux disease (GERD)." | 5.34 | Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study. ( Chang, TE; Hou, MC; Huang, YH; Lee, FY; Lin, XH; Luo, JC; Ting, PH, 2020) |
| " After undergoing 1 year of voriconazole therapy for pulmonary aspergillosis, a 44-year-old man began treatment with 30 mg lansoprazole for gastroesophageal reflux symptoms." | 4.93 | Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature. ( Lopez, JL; Tayek, JA, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, XH | 1 |
| Luo, JC | 1 |
| Ting, PH | 1 |
| Chang, TE | 1 |
| Huang, YH | 1 |
| Hou, MC | 1 |
| Lee, FY | 1 |
| Lopez, JL | 1 |
| Tayek, JA | 1 |
1 review available for lansoprazole and Dyslipidemias
| Article | Year |
|---|---|
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
Topics: Adult; Antifungal Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Cytochrome P-45 | 2016 |
1 trial available for lansoprazole and Dyslipidemias
| Article | Year |
|---|---|
Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
Topics: Aged; Cough; Dexlansoprazole; Dyslipidemias; Esophagitis; Female; Gastroesophageal Reflux; Globus Se | 2020 |